[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 253
Citations 0
Evidence-Based Dermatology: Research Commentary
Mar 2012

A Randomized Controlled Trial of Belimumab for the Treatment of Active Systemic Lupus Erythematosus

Arch Dermatol. 2012;148(3):376-378. doi:10.1001/archdermatol.2011.1266

Commentary on: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialNavarra SV, Guzm án RM, Gallacher AE, et al. Lancet. 2011;377(9767):721-731

Question: In patients with serologically active systemic lupus erythematosus (SLE), does the addition of belimumab to standard care improve disease activity?

Design: Double-blind, parallel-group, randomized, placebo-controlled trial.

First Page Preview View Large
First page PDF preview
First page PDF preview
×